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Purpose/Objective: Re-irradiation of high-grade glioma (HGG) using 
modern delivery techniques and advanced imaging 18F-flouroethyl-
tyrosine (FET)-PET and MRI have not been systematically evaluated. 
The initial results of a prospective, FET-PET and MRI-guided, dose-
escalation study of previously irradiated HGG are presented.  
Materials and Methods: Patients with performance status 0-2 with 
localized disease progression despite standard therapy were eligible 
to be included. The target was defined using MRI (Siemens 1.5 T 
scanner, T1 w/Gd contrast) and FET-PET (Siemens mCT brain scanner 
20 min after injection of 200 MBq FET, threshold: 1.6 of SUV mean in 
background) and these volumes were fused. A 2 mm PTV (planning 
target volume) margin was added. Hypofractionated stereotactic 
radiotherapy (SRT) was planned in Eclipse dose planning system 
(Varian) and given as Volumetric Modulated Arc Therapy on a Novalis 
Tx accelerator (Varian/BrainLab). Total doses to organs at risk 
(brainstem, optic chiasm) were calculated using primary and current 
treatment plans.  
Results: Fifteen patients were referred to treatment in dose level one 
(3.5 Gy x 10, 5 F/W) between December 1, 2011 and August 1, 2012. 
Twelve were eligible to be included. Histological diagnoses were 
glioblastoma multiforme (83%) and anaplastic astrocytoma WHO grade 
III. All patients had received prior focal radiotherapy (44 Gy-60 Gy) 
and the median interval since primary RT was 26.7 months (range: 
14.3-67.7 months). In 11/12 cases increased FET uptake consistent 
with malignant disease was detected. The median GTV MR (defined by 
T1 MR with contrast) was 23.8 cm3 (range: 7.9-52.4 cm3). The 
combined GTV used for planning (based on MRI and PET) was larger 
than the GTV MR for 11 out of 12 patients by a median of 26% (range: 
0-283%). The median PTV volume was 53.4 cm3 (range: 21.1-91.3 
cm3). The median doses to chiasm and brainstem were 0.9 (range: 
0.2-22.8 Gy) and 1.2 (range: 0.4-26.9 Gy) in 2-Gy equivalent fractions 
(α/β=3), respectively. Doses to the chiasm and brainstem exceeded 15 
Gy in 1 and 2 cases of temporal tumors, respectively. All patients 
completed treatment as planned. No serious (grade 2+ CTC) acute 
adverse events were observed during treatment or in the 4 following 
weeks. One patient experienced dizziness and unilateral motor 
dysfunction 4 weeks after treatment. Disease progression was 
suspected but the patient withdrew from the study. No serious late 
side effects have been observed. Minimum follow-up time for all 
(surviving) patients is currently 3 months.  
Conclusions: Re-irradiation using 3.5 Gy x 10 to localized recurrences 
of HGG using MR and FET-PET for target delineation was feasible and 
well tolerated. Using FET-PET for target delineation increased the size 
of the GTV by a median of 26%. Only in case of temporal tumors did 
doses to organs at risk pose a planning challenge. The study is ongoing 
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Purpose/Objective: Standard therapy for patients with brain 
metastases was WBRT with 30Gy/10fx in our institution. We report 
about our newly developed radiotherapy procedure with 
hypofractionated dose intensification to metastases with or without 
simultaneously applied low dose prophylactic cranial irradiation (PCI) 
to the remaining brain. 
Materials and Methods: From 6/2010 until 5/2012 61 patients with 1-
4 brain metastases and Karnofsky performance score > 50 were 
treated with our new therapy concept. 21 Patients received local 
treatment only whereas 40 patients assumed to have a higher risk for 
new distant brain metastases were treated with simultaneous low 
dose PCI. 20 patients were irradiated after gross tumour resection. 
Macroscopic metastases were treated to 60Gy/15fx (BED10 84Gy, 
BED3 140Gy) and PCI was applied with 27Gy/15fx (BED10 32Gy, BED3 
43Gy) using RapidArc technique with simultaneous integrated boost 
(SIB). Following resection of the metastasis the resection cavity was 
irradiated to 48Gy/15fx (BED10 63Gy), residual/unresected 
macroscopic tumour to 60Gy/15fx and the remaining brain if indicated 
to 27Gy/15fx (PCI). CTV was equal to GTV and a 3-5 mm margin was 
used for the PTV PTV. The minimum dose for the metastases was 95% 
of the prescribed dose, whereas the median dose for the whole brain 
was 27 Gy. All patients were followed prospectively with CT or MRI 
scan every 2-4 months until deterioration. Toxicity was assessed by 
the treating physician using CTCAE 4.0. Statistical analysis was 
performed with Kaplan Meier and Logrank test. Multivariate analysis 
was performed using Cox-regression.  
Results: The median follow-up was 10.7 months (range 4.1-26.1 
months). The treatment was well tolerated and no grade 3 or higher 
acute toxicity was observed. One patient with 4 small metastases who 
was treated with 60Gy/15fx and PCI died possibly due to progressive 
radionecrosis 15 months after treatment. Local recurrence-free 
survival after treatment with 60Gy/15fx has been 100%, whereas one 
metastasis relapsed after resection and postoperative RT (48Gy/15fx). 
Regional recurrence-free survival within 9 months was 68% with PCI 
and 59% without PCI, respectively (p=0.23). 39 patients died during 
follow-up and the overall survival at 12 months was 44%. Median 
survival time in univariate analysis was significantly better for 
patients younger than 60 years (13.0 vs. 7.5 months, p=0.03), patients 
with RPA I (18 vs. 7.6 months, p=0.005), patients with controlled 
extracranial disease (15 vs. 7 months, p=0.005) and patients who 
received PCI (11.5 vs. 6.3 months, p=0.02). Gross tumour resection 
and solitary metastasis did not result in significantly better survival. In 
multivariate Cox regression analysis RPA I class and PCI remained 
statistically significant predictors for improved survival. 
Conclusions: Dose intensified irradiation to macroscopic brain 
metastases or resection cavities can be combined with a well 
tolerated prophylactic cranial irradiation using SIB. Local tumour 
control appears to be excellent, distant brain failure was moderate 
and overall survival was promising. 
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Purpose/Objective: To define the maximum tolerable dose (MTD) of 
temozolomide concomitant to radiotherapy in patients with Primary 
Central Nervous System Lymphoma (PCNLSL), previously treated with 
high dose Methotrexate (HD-MTX). 
Materials and Methods: Patients (≥18 yrs) with histologically proven 
diagnosis of PCNSL, treated with two cycles of HD-MTX, were 
enrolled. For radiation treatment, Clinical Target Volumes (CTVs) 
were: whole brain plus leptomeninges until C2 (CTV2) (30 Gy in 15 
fractions), and initial site of disease plus residual mass if present 
(CTV1) (3600-4600 cGy depending on HD-MTX response). Dose 
escalation of concomitant Temozolomide (TMZ) until standard 
concomitant to radiotherapy dose advanced using a standard 3+3 
